Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Author(s): Jonathan W. Friedberg; 1; Rodolfo Bordoni; 2; Dipti Patel-Donnelly; 3; Timothy Larson; 4; Jerome Goldschmidt; 5; Ralph Boccia; 6; Vivian J. M. Cline; 7; Adrija Mamidipalli; 8; Jingmin Liu; 8; Alev Akyol; 9; Christopher A. Yasenchak10
Source: Blood (2024) 143 (9): 786–795.

Dr. Maen Hussein's Thoughts

A non-chemotherapy option for frail patients with advanced cHL. Brentuximab and nivolumab seems to be promising for those patients.

ABSTRACT

Older patients with advanced-stage classical Hodgkin lymphoma (cHL) have inferior outcomes compared with younger patients, potentially due to comorbidities and frailty. This noncomparative phase 2 study enrolled patients aged ≥60 years with cHL unfit for conventional chemotherapy to receive frontline brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2) (part B) or nivolumab (part D; 3 mg/kg). In parts B and D, 50% and 38% of patients, respectively, had ≥3 general comorbidities or ≥1 significant comorbidity. Of the 22 patients treated with BV-DTIC, 95% achieved objective response, and 64% achieved complete response (CR). With a median follow-up of 63.6 months, median duration of response (mDOR) was 46.0 months. Median progression-free survival (mPFS) was 47.2 months; median overall survival (mOS) was not reached. Of 21 patients treated with BV-nivolumab, 86% achieved objective response, and 67% achieved CR. With 51.6 months of median follow-up, mDOR, mPFS, and mOS were not reached. Ten patients (45%) with BV-DTIC and 16 patients (76%) with BV-nivolumab experienced grade ≥3 treatment-emergent adverse events; sensory peripheral neuropathy (PN; 27%) and neutropenia (9%) were most common with BV-DTIC, and increased lipase (24%), motor PN (19%), and sensory PN (19%) were most common with BV-nivolumab. Despite high median age, inclusion of patients aged ≤88 years, and frailty, these results demonstrate safety and promising durable efficacy of BV-DTIC and BV-nivolumab combinations as frontline treatment, suggesting potential alternatives for older patients with cHL unfit for initial conventional chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01716806.

Author Affiliations

1Wilmot Cancer Institute, University of Rochester, Rochester, NY; 2Georgia Cancer Specialists, Marietta, GA; 3Virginia Cancer Specialists, Fairfax, VA; 4Minnesota Oncology PA, Minneapolis, MN; 5Oncology and Hematology Associates of SW Virginia, Blacksburg, VA; 6Center for Cancer and Blood Disorders, Bethesda, MD; 7Texas Oncology, Austin, TX; 8Seagen Inc, Bothell, WA; 9Bristol Myers Squibb, Princeton, NJ; 10Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles